Calendar of Events
Presented by
Manish Patankar, PhD
Professor, Obstetrics & Gynecology, Division of Reproductive Sciences
Associate Director, Endocrine and Reproductive Physiology (ERP) Program
University of Wisconsin-Madison, School of Medicine and Public Health
About
Dr. Manish Patankar is a Professor in the Division of Reproductive Sciences. Dr. Patankar grew up in Thane, India, a city that borders Mumbai (Bombay). His wife is a physical therapist at the American Family Children’s Hospital and they have a 7 year old daughter who is in first grade at Glenn Stephens Elementary.
Dr. Patankar graduated from the University of Bombay, India with a B.S. in Chemistry in 1987. Subsequently, he received his Masters of Science in Organic Chemistry from the University of Bombay in 1990, and his Masters of Chemistry from Old Dominion University in Norfolk, Virginia in 1993. Dr. Patankar then completed his PhD in Biomedical Sciences at Eastern Virginia Medical School/Old Dominion University in 1998.
Dr. Patankar was an instructor and Research Professor at Eastern Virginia Medical School until 2004 when he joined the department as Professor and also became a member of the UW-Madison Carbone Cancer Center. His current research includes developing diagnostic tests for ovarian cancer and preeclampsia and strategies for treating ovarian cancer.
Collaborations at UW-Madison include: Drs. Joseph Connor, David Abbott, Paul Sondel, David Beebe, Ralph Albrecht, Mark Cook, Sean Fain, Ian Rowland, Hirak Basu and and Lingjun Li. Non UW-Madison collaborations include: Drs. Mitchell Ho and Ira Pastan (National Cancer Institute), Dr. Jennifer Gubbels (Augustana College, SD), Rebecca Whelan (Oberlin College, OH), Biotech Industry: Neoclone Biotechnology (Madison), and Gentel Biosciences (Fitchburg).
Dr. Patankar teaches Endocrine Physiology, Biology 151, and lectures on immunology in several different courses on campus.
What does he do in this spare time? He loves music and watching SpongeBob with his daughter.
One of the most interesting places that Dr. Patankar has visited is Bergen, Norway.
Research Focus
The primary focus of my research is to devise specific methods for early diagnosis of epithelial ovarian cancer (EOC) and to understand the effect of factors produced by ovarian tumors on the functional capacity of tumor infiltrating lymphocytes. This research involves extensive utilization of glycoproteomic analysis in conjunction with cellular immunology, molecular biology and glycobiology.
Presented by
Stephanie Olivier-Van Stichelen, PhD
Assistant Professor, Biochemistry
Medical College of Wisconsin
About
Dr. Olivier-Van Stichelen received her PhD degree in Biochemistry from the University of Lille, France in 2012. Her work was focused on the understanding of the nutrient-sensing O-GlcNAcylation in colorectal cancer development with a special interest in diet-dependent modification of the oncogene beta-catenin.
After completion of her degree, she was appointed as a post-doctoral Fellow in the Laboratory of Cellular and Molecular Biology at the National Institute of Health, Bethesda, MD, USA. In this lab, Dr. Olivier-Van Stichelen worked on different aspects of O-GlcNAcylation during development including X-inactivation of the O-GlcNAc Transferase gene. She also developed a brain O-GlcNAcase knockout model and studied the impact of sugar consumption during pregnancy on O-GlcNAc-dependent development of metabolic homeostasis. More recently, she developed interests in understanding the importance of artificial sweeteners for offspring’s metabolism and microbiome.
Dr. Olivier-Van Stichelen established her lab at the Medical College of Wisconsin at the crossroad of sweeteners, pregnancy, development and metabolism.
Research Focus
Due to the global trend of growing sweetener consumption, determining the interplay between diet and pre- and post-natal development is emerging as a critical area for research. Currently, the average American eats around 22 teaspoons of added sugar every day (30 sugar cubes/day hidden in foods). This modern glucose-rich diet correlates with an increase in the prevalence of obesity, diabetes and others metabolic syndromes. Moreover, the effort to reduce sugar consumption has led people to consume more non-caloric sweeteners (Aspartame, Sucralose, Acesulfame-K…). While they appear healthier for glucose homeostasis than a high carbohydrate diet, recent studies have shown that artificial sweeteners impact glucose metabolism as well as gut microbiota, rising questions about their excessive use.
Therefore, understanding what happens when caloric and non-caloric sweeteners are metabolized is of utmost importance for public health and the focus of my research group.
Nutrient-dependent O-GlcNAc cycling in development and disease
O-GlcNAcylation is one of the key components of diet-responsive signaling. This unique glucose rheostat is a ubiquitous and dynamic glycosylation of intracellular proteins with approximately 1000 modified proteins described to date. Two key enzymes drive O-GlcNAc cycling: The O-GlcNAc transferase (OGT) adds the modification and the O-GlcNAcase (OGA) removes it. Although many studies have focused on the decrease or complete absence of O-GlcNAc cycling by modulating the expression or activity of OGT, only a few studies have targeted hyper-O-GlcNAcylation by disturbing OGA. Because this post-translational modification is directly dependent on glucose input, depleting OGA creates an artificial and constant hyperglycemia-induced O-GlcNAcylation state. Using Oga and Ogt knockout (KO) cellular and mouse models, we can decipher the impact of high carbohydrate diet on embryonic development.
Non-Nutritive Sweeteners in pregnancy and lactation
Part of my lab is interested in understanding the impact of Non-Nutritive Sweetener (NNS) consumption through pregnancy and lactation. Although, NNS have been found in mother’s milk and in placental blood circulation, no study has focused on the fundamental effect of those non-caloric sweeteners on the developing organism.
Among the impacts described in adults are changes in intestinal hormonal secretion, glucose metabolism and most fascinating, re- duction of the gut microbiota. Nevertheless, the fundamental mechanisms of those changes are far from understood. Glycoproteins found on the surface of the intestinal epithelium define the glycocalyx and are an essential mammalian mechanism of communication with the gut microbiome. Their reciprocal relationship with the gut microbiome regulates not only nutrient breakdown, and food absorption, but also infection. We are convinced that by altering both microbiome and the detoxification process, NNS exposure in early life will impact metabolic homeostasis later in life.
Presented by
Xiaowen Bai, MD, PhD
Xiaowen Bai, MD, PhD
Associate Professor, Cell Biology, Neurobiology & Anatomy
Medical College of Wisconsin
About
Dr. Bai’s research interests are centered on the application of stem cells on disease modeling and tissue regeneration. The current major focus of the laboratory is to utilize gain- and loss-of-function approaches to examine the novel molecular mechanisms underlying the roles of non-coding RNAs, mitochondria, and genetic factors in neurodegeneration and cardiotoxicity in mice, and translate the findings to humans using stem cell-derived brain cells, heart cells, three-dimensional mini brains, and heart organoids.
Research Area 1:
Non-coding RNAs, mitochondria, and cell stress-related genes in neurodegeneration:
Neurological disorders have emerged as a predominant healthcare concern in recent years due to their severe consequences on quality of life and prevalence throughout the world. Understanding the underlying mechanisms of these diseases and the interactions between different brain cell types is essential for the development of new therapeutics. Many drugs (e.g., anesthetics), environmental factors (e.g., alcohol), diseases, and genetic risks are related to neurodegeneration. We examine the novel molecular mechanisms underlying the roles of microRNAs, long non-coding RNAs, mitochondria, immediate early and other cell stress-related genes in neurodegeneration using both mouse, and human stem cell-derived brain cell and three-dimensional mini brain models
Research Area 2:
Stem cell-mediated myocardial regeneration
Myocardial infarction is one of the major causes of death throughout the world. Currently, there is not a highly effective approach for treatment. Stem cells hold promise in repairing injured cardiac tissue. Our lab is involved in studying the effect of the transplantation of adipose tissue-derived stem cells and induced pluripotent stem cell-derived cardiomyocytes on myocardial regeneration following ischemia injury. A molecular imaging method has been developed to investigate the molecular mechanisms controlling homing, engraftment, and survival of injected cells in vivo.
Research Area 3:
The mechanisms of impaired cardioprotection under diabetic conditions
Hyperglycemia has been shown to be particularly detrimental to the cardioprotective effects, with the underlying mechanisms remaining largely unknown. We have developed and validated a clinically relevant model of functional human cardiomyocytes derived from both normal induced pluripotent stem cells (iPSCs) and diabetes mellitus iPSCs. This in vitro model of human disease will enable developmental and comparative studies of normal and diabetic cardiomyocytes to address genetic and environmental mechanisms responsible for attenuation of cardioprotection signaling in diabetics.
Presented by
Paul Campagnola, PhD
Professor, Biomedical Engineering
University of Wisconsin-Madison
About
Campagnola’s research is directed toward developing high resolution imaging modalities. The technologies his group has developed can readily be applied to problems in eye and vision research. For example, the technique of Second Harmonic Generation (SHG) to image collagen fibrillar structure has been used by other labs to image the corneal structure. Expanding into eye research is a natural direction for the Campagnola Laboratory.
Alterations to the extracellular matrix (ECM) composition and structure are thought to be critical for tumor initiation and progression for several epithelial carcinomas, including those of the ovary and breast. Our lab develops Second Harmonic Generation (SHG) microscopy tools to quantitative assess these alterations in the stroma where we correlate the optical signatures with structural changes in the fibrillar assembly between normal and diseased tissues. This physical approach provides objective measurements that may be used to understand disease progression. To further investigate how remodeling enables invasion and metastasis in vivo we use multiphoton excited (MPE) photochemistry to fabricate biomimetic in vitro models of the ovarian ECM. The nano/microstructured models simulate the crosslinked fibrillar structure of the native ECM.
Tissue engineering has vast potential to improve human health by repair and maintenance of existing tissue or generation of replacement of tissues and organs. A major limitation has been an incomplete understanding of the underlying cell-ECM interactions that govern cell adhesion which will ultimately affect downstream functions. Our approach to this problem utilizes MPE photochemistry to create 3D biomimetic scaffolds directly from crosslinked proteins. Beginning with bio-inspired designs we will seek to achieve improved function.
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]Resident and Fellow Research and Alumni Day is an annual event where our residents and graduating fellow present their clinical, translational science, and educational research results within their residency and fellowship in the Department of Obstetrics and Gynecology.
Featuring The Roland S. Cron Lectureship
Guest Speaker
Kristyn Melíssa Brandi, MD, MPH
Board Chair
Physicians for Reproductive Health
About Dr. Brandi
Dr. Kristyn Brandi (pronouns: she/her/ella) is an Assistant Professor at Rutgers – New Jersey Medical School, where she completed her medical school and residency. She completed a Family Planning Fellowship at Boston University where she also earned her Master’s in Public Health with a concentration in Health Law, Bioethics and Human Rights. Her research is on reproductive decision making, contraceptive coercion, and racism in reproductive health care. She serves as the Board Chair of Physicians for Reproductive Health, sits on several sub-committees for the Society of Family Planning and is a founding member of Centering Equity, Racial and Cultural Literacy in Family Planning (CERCL-FP). She proudly identifies as a Latina pansexual abortion provider.
Agenda
| Time | Activity |
|---|---|
| 7:15am | GRAB AND GO BREAKFAST |
| 7:45am | WELCOME & INTRODUCTIONS |
| 8:00am | Christine Livergood, MD, MFM Fellow Characterization of RhoBTB1, a PPARγ target gene, in the Placenta Mentors: Curt Sigmund, PhD & Jenn McIntosh, MD |
| 8:15am | Jordan Hauck, DO, R3 Risk of unplanned healthcare utilization in post-partum period for patients with hypertensive disorders of pregnancy Mentor: Anna Palatnik, MD |
| 8:30am | Leigh Mahlum, MD, R3 Factors associated with persistent hypertension at 1-year postpartum in patients with gestational hypertension or preeclampsia Mentor: Anna Palatnik, MD |
| 8:45am | Sarah Amherdt, MD, R3 Incidence of adverse pregnancy outcomes based on the degree of short interpregnancy interval in urban Milwaukee population Mentor: Anna Palatnik, MD |
| 9:00am | Zack Schoppen, MD, R3 What To Expect When You’re Expecting a Medical Student Mentor: Kate Dielentheis, MD |
| 9:15am | Steph Nguyen, MD, R3 Continuity of Care and Non-Urgent Health Care Utilization Mentors: Jessica Francis, MD & Stephen McAvoy, MD |
| 9:30am | BREAK |
| 9:45am | Alex Petrie, MD, R3 Evaluating the use and utility of a Weight Loss Clinic referral after surgical treatment of Endometrial Cancer Mentor: Erin Bishop, MD |
| 10:00am | Katie Pellino, MD, R3 Post-Discharge Opioid Prescribing After Cesarean: A Quality Improvement Initiative Mentor: Erika Peterson, MD |
| 10:15am | David Eggert, DO, R2 The Influence of Patient Education Level, Infertility Treatment, and Pregnancy and Breastfeeding Status on Perceptions of the COVID-19 Vaccine: A Mixed Methods Study Mentor: Stephanie Gunderson, MD |
| 10:30am | Rebecca Sigourney, MD, R2 Investigating the Impact of the Addition of a MIGS Surgeon on Surgical Volume of General OBGYNs Mentor: Ben Beran, MD |
| 10:45am | BREAK |
| 11:00am | The Roland S. Cron Lecture: Kristyn Melíssa Brandi, MD, MPH Title: "Who is in Control Here- Contraceptive Coercion and Reproductive Justice" |
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]
Presented by
Hallgeir Rui, MD, PhD
WBCS Endowed Professor of Breast Cancer Research
Vice Chair of Research, Department of Pathology
Director of MCW Tissue Bank
Associate Director of Shared Resources, MCW Cancer Center
Medical College of Wisconsin
About
Hallgeir Rui, MD, PhD is internationally recognized for his research on hormone signaling in breast cancer, and has a strong track record of leadership, mentoring and collaboration. He is the WBCS Endowed Professor of Breast Cancer Research at the Medical College of Wisconsin (MCW), with his primary appointment in the Department of Pathology, and a secondary appointment to the Department of Pharmacology & Toxicology. In addition, Dr. Rui serves as the Associate Director of Basic Science and Shared Resources at the MCW Cancer Center. With his past experience as a Program Leader and Shared Resource Director at the NCI-designated Sidney Kimmel Cancer Center at Thomas Jefferson University, Dr. Rui brings valuable experience to the MCW Cancer Center efforts toward NCI-designation. Dr. Rui serves on the Breast Cancer Translational Research Committee of NRG Oncology.
A central focus of hisresearch is on molecular profiling of solid tumors, with published track record in malignancies of the breast, pancreas, prostate, colon, head and neck and melanomas. Key areas of interest are therapy-relevant protein expression, including pathway-activation status and tumor immunology-related markers, with development of better predictive markers and improved personalized cancer care as the overarching goal. Efforts are dedicated to improving methods and applications for quantitative, multiplex immunohistochemistry (IHC) for single-cell protein marker analyses – histocytometry – in solid tumors.
His laboratory invented novel ultrahigh density tissue arraying technology termed cutting-edge matrix assembly (CEMA) that overcomes limitations of core-based tissue arrays (US patent 8,349,584). Our laboratory, in collaboration with Dr. Kay-Uwe Wagner, developed novel prolactin-humanized NSG-Pro mouse strain for more accurate modeling and drug response testing of human breast cancer and other prolactin receptor-positive cancers, and my team has established a panel of new patient-derived breast cancer xenograft models in NSG-Pro mice.
Dr. Rui has extensive experience in facilitating multidisciplinary and collaborative program projects, including a concluded $6.7 million Promise Project Award funded by Susan G. Komen Foundation. Attesting to the productive use of immunofluorescence-based quantitative histocytometry and tissue arraying technologies for high-throughput application of innovative and nonstandard technologies for immunoprofiling of solid tumors, I led a multidisciplinary team that quantified levels of more than 100 therapy-relevant protein markers in nearly 3,000 breast cancer specimens, using tissue arrays and accompanying clinical data assembled and procured by a consortium of five institutions. As the leader of this consortium, I coordinated extensive efforts to combine tissue resources, data, equipment resources and broad areas of expertise.
Learn more about the WHRP Seminars[/vc_column_text][/vc_column][/vc_row]
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]
Presented by
Victor Jin, PhD
Linda T. and John A. Mellowes Endowed Chair of Bioinformatics and Data Analytics
Director, Bioinformatics Shared Resources
Professor, Institute for Health and Equity/Biostatistics
Medical College of Wisconsin
About
Dr. Jin has extensive experience in developing computational and genomics approaches for analyzing various omics-seq data, and runs a systems biology lab with a balanced dry and wet components.
Research Interests:
1) Developing genomics and computational approaches for the identification of three-dimensional (3D) chromatin interactions from the various omics-seq data.
2) Functionally and mechanistically characterizing the roles of epigenetic marks in cancer development and progression using novel techniques such as 3C/ChIP/RT-qPCR, 3D-FISH and CRISPR/Cas9.
3) Adapting/applying genome-wide omics-seq techniques in patient tissues to identify epigenetic-driven therapeutic targets and biomarkers.
Learn more about the WHRP Seminars[/vc_column_text][/vc_column][/vc_row]
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]Resident and Fellow Research and Alumni Day is an annual event where our residents and graduating fellow present their clinical, translational science, and educational research results within their residency and fellowship in the Department of Obstetrics and Gynecology.[/vc_column_text][vc_separator type=”normal” thickness=”3″][vc_empty_space height=”20px”][/vc_column][/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column width=”1/2″][vc_column_text]You must register for this in-person event:[/vc_column_text][vc_empty_space height=”12px”][/vc_column][vc_column width=”1/2″]Register Now![/vc_column][/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_separator type=”normal” thickness=”3″][vc_column_text]
Schedule:
[/vc_column_text][vc_column_text]
| Time | Activity |
|---|---|
| 7:15am | BREAKFAST |
| 7:45am | WELCOME & INTRODUCTIONS |
| 8:00am | Yiwen Cui, MD, MFM Fellow O-GlcNAc transferase contributes to sex-specific placental deregulation in gestational diabetes Mentor: Stephanie Olivier-Van Stichelen, PhD |
| 8:15am | Lindsay McAlarnen, MD GYN ONC Fellow Exosomal FXR1 as a translational mediator in the ovarian cancer microenvironment Mentor:Pradeep Chaluvally-Raghavan, PhD |
| 8:30am | Rebekah Summey, MD GYN ONC Fellow Exploration and exploitation of hormonal pathways in adult granulosa cell tumors for development of targeted therapeutics Mentors: Elizabeth Hopp, MD and Janet S. Rader, MD |
| 8:45am | Alex Levy, MD, R4 Is One Superior? Comparison of Early Removal Rates of Intrauterine Device versus Nexplanon Subdermal Implant in Women Ages 16-24 in Milwaukee, Wisconsin Mentor: Jessica Francis, MD |
| 9:00am | Rana Aliani, MD R3 Impact of Race, Insurance, and Procedural Timing on Sterilization Method Mentor: Ben Beran, MD |
| 9:15am | Mary Siracusa, MD R3 Determining Patients’ Preferred Ultrasound Provider During the Preoperative Evaluation of Endometriosis Mentor: Ben Beran, MD |
| 9:30am | BREAK |
| 9:45am | Iman Khan, MD R3 Postpartum Care in a Post-COVID Era Mentors: Amy Domeyer, MD and Erika Peterson, MD |
| 10:00am | Blake Neuburg, MD R3 Inpatient Versus Outpatient Management of Gestational Hypertension or Preeclampsia Without Severe Features Mentor: Anna Palatnik, MD |
| 10:15am | Ankita Sarawagi, MD R3 Screening rates for intimate partner violence (IPV) in the OBGYN clinic from 2019 to 2022 Mentor: Kim Gecsi, MD |
| 10:30am | Margaret Bruce, MD R3 Evaluating Modern Contraceptive Methods as Risk Factors for Recurrent UTI’s Mentor: Sumana Koduri, MD |
| 10:45am | BREAK |
| 11:00am | The Roland S. Cron Lecture: Nandini Raghuraman, MD, MS Fellowship Program Director, Maternal-Fetal Medicine Assistant Professor, OB/GYN Washington University School of Medicine "Moving Evidence into Clinical Practice on Labor & Delivery" |
| 12:00pm | Questions for Dr. Raghuraman |
| 12:30pm | Lunch |
Featuring The Roland S. Cron Lectureship
Guest Speaker
Nandini Raghuraman, MD MSCI
Fellowship Program Director, Maternal-Fetal Medicine
Assistant Professor, OB/GYN
Washington University School of Medicine
About Dr. Raghuraman
Nandini Raghuraman, MD, MSCI, is an Assistant Professor in the Division of Maternal-Fetal Medicine at Washington University in St Louis and the MFM Fellowship Program Director. She is a NIH-funded physician scientist with expertise in Labor & Delivery clinical trials and implementation science in obstetrics. She has authored over 70 peer reviewed manuscripts and is currently leading a multicenter randomized trial investigating the effect of maternal oxygen supplementation in labor for fetal resuscitation.
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]
Presented by
Wei Xu, PhD
Professor of Oncology, Marian A. Messerschmidt
Associate Director,, McArdle Laboratory for Cancer Research
Director of MCW Tissue Bank
Co-Director, Genetic and Epigenetic Mechanism Program, Carbone Cancer Center
About
Dr. Xu’s laboratory explores the protective roles of environmental and nutritional estrogenic compounds in mammals for breast cancer prevention and treatment. Estrogen receptors (ERs) exist in two forms, ERa and ERb, which have opposing roles in cell proliferation. Estrogenic compounds can control balance between mammary cell proliferation and differentiation via stimulating the formation of different forms of ER dimers. Xu lab has developed the Bioluminescent Resonance Energy Transfer (BRET) assays for detecting in vivo homodimerization and heterodimerization of ERa and ERb induced by estrogenic compounds. Biological functions of these estrogenic compounds are currently being investigated in cell-based and breast cancer mouse models. Dr. Xu’s laboratory has also employed biochemical and functional genomic approaches, as well as mouse genetics to decipher the contribution of histone arginine methylation to the epigenetic control of cancer cells. The major focus of Xu lab is on a protein arginine (R) methyltransferase CARM1/PRMT4, a nuclear hormone receptor co-activator. Dr. Xu has identified a number of non-histone substrates for CARM1 and is in the progress of elucidating the functions of protein arginine methylation in breast cancer initiation and progression.
Learn more about the WHRP Seminars[/vc_column_text][/vc_column][/vc_row]
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]
Presented by
Bo Wang, PhD
Director – Tissue Regenerative Engineering Laboratory (TRE Lab)
Assistant Professor – Department of Biomedical Engineering, The Marquette University and Medical College of Wisconsin
About
Dr. Bo Wang, Director and Principal Investigator of the TRE Lab, received her PhD in Biomedical Engineering from Mississippi State University in 2012 and completed her Postdoctoral Fellowship at Northwestern University’s Feinberg School of Medicine, Department of Surgery, in 2016. She joined the Marquette-MCW Joint Department of Biomedical Engineering in January of 2019 with research interests that include stem cell engineering, hard-tissue engineering and 3D bioprinting, as well as vascular tissue engineering, imaging, modeling and simulation.
The Tissue Regenerative Engineering Laboratory is developing bio-functional engineered tissues that provide advanced therapeutic options for such conditions as birth defects, bone disorders, and liver and vascular diseases. To do this, the TRE Lab will first develop a greater understanding of the biological and molecular processes involved in regenerative regression.
Learn more about the WHRP Seminars[/vc_column_text][/vc_column][/vc_row]
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” z_index=””][vc_column][vc_column_text]
Presented by
Navonil De Sarkar, PhD
Assistant Professor – Department of Pathology at the Medical College of Wisconsin
About
Navonil De Sarkar is an Assistant Professor at the Medical College of Wisconsin Cancer Center with a dual background in computational and experimental genomics; he brings a multidisciplinary approach to studying human cancers. His research focuses on understanding the natural history of the disease, devising noninvasive approaches to track adaptive and molecular evolutionary changes in cancer accurately, and ultimately developing practical strategies for precision medicine in advanced cancer patients (Augmented precision medicine).
Navonil received his Ph.D. from the Indian Statistical Institute and joined Peter Nelson’s lab at the University of Washington & Fred Hutchinson Cancer Research Center, Seattle, for postdoctoral training. Through adopting integrative genomics approaches, Navonil developed extensive experience analyzing tumor genomes to study functionally relevant mutations and structural aberrations using tumor tissue and circulating tumor DNA (ctDNA). Navonil participated in several large-scale consortium data analyses, including Stat-up-to-cancer germline and prostate tumor analysis efforts. Navonil led the bioinformatics analysis of the large-scale germline sequence work that highlighted the importance of inherited DNA repair genes in shaping the fate of advanced prostate cancer. He is one of the early discoverers of CDK12 loss-associated tandem duplicator signature. Subsequently, De Sarkar developed a machine learning-based classifier that accurately predicts functional homologous recombination deficiency. Recently, he co-led a study interrogating whole genomes of advanced prostate cancers using cell-free DNA sequencing and discovered imprints of cancer epigenomes in native cell-free DNA sequence data.
Navonil is a recipient of several trainee awards. To mention in 2019 Navonil received the very competitive Prostate Cancer Foundation Young Investigator Award. Then onwards, Navonil is co-leading Prostate Cancer Foundation DNA repair-focused working group activities. He is the editorial board member for Translational Oncology and an associate editor for the Genitourinary Oncology edition of Frontiers journals.
Navonil re-joined MCW in March 2023 and committed to establishing a multidisciplinary research group to develop cutting-edge but practical precision medicine tools for prostate and other cancers. Building on strong biological fundamentals and detailed understandings of the disease, De Sarkar Lab (DeTAnomics Lab) is developing novel therapeutic strategies and working to co-develop new genomic assays and computational genomics tools to help us tackle the most lethal types of prostate and other cancers. DeTAnomics Lab adopts long-read genomic sequencing techniques to better understand cancer genome, transcriptome, and epigenome. In the lab, DeTAnomics lab explores the complex interplay between the genome and epigenome to uncover new insights that can lead to the development of more effective therapeutics and biomarkers. Currently, DeSarkar and his team are working on developing a practical strategy to degrade BRCA2 in tumor cells so as to confer DNA-damaging mediated therapy benefits to a wider pool of patients.
Learn more about the WHRP Seminars[/vc_column_text][/vc_column][/vc_row]